AI Article Synopsis
- - A 41-year-old woman with severe rheumatoid arthritis, resistant to multiple treatments, was given the monoclonal antibody Campath 1H.
- - She experienced significant clinical improvement within 24 hours, which lasted for 12-14 weeks, along with a suppression of lymphocyte count for 7 months.
- - The treatment showed no major side effects and no adverse immune response, indicating potential benefits for rheumatoid arthritis therapy.
Article Abstract
A 41-year-old woman with active, seropositive erosive rheumatoid arthritis was treated with the humanized monoclonal antibody Campath 1H. She had not responded or developed side effects to myocrisin, sulfasalazine and penicillamine, and had not responded to inpatient bedrest and physiotherapy. There was a rapid clinical improvement within 24 hours of infusion, which was maintained for about 12-14 weeks after the infusion. The lymphocyte count was suppressed for 7 months after treatment. There were no significant side effects during or after treatment. No anti-Campath 1H response was detected. This preliminary study suggests humanized monoclonal antibody therapy may be of value in the treatment of rheumatoid arthritis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!